Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 13%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Veracyte Inc has demonstrated strong financial performance, with a non-GAAP operating margin of 28.8%, reflecting a significant year-over-year increase of 830 basis points. The company's genomic test volume reached approximately 45,888, showing an 18% growth, while testing revenue surged to $127.8 million, marking a 17% increase in 3Q25. Additionally, management has raised its guidance for adjusted EBITDA margin for 2025 to approximately 25.0%, indicating robust improvement from previous years and a positive outlook for sustained growth.

Bears say

Veracyte Inc. faces significant risks that could negatively impact its financial performance, including weaker-than-expected sales for its Decipher and Afirma tests, deteriorating operating margins, and unfavorable free cash flow projections. Revenue per test showed a decline to $2,784 in 3Q25, suggesting challenges in maintaining pricing power, while management's adjusted EBITDA margin guidance for 2026 has decreased to approximately 25% from 27.5% in the previous year. Additionally, the company's genomic test volume growth has slowed, with a projected bear case scenario indicating sustained revenue growth at less than 13%, driven by anticipated underperformance in both line of products and overall margin pressures.

Veracyte (VCYT) has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 8 analysts, Veracyte (VCYT) has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.